VALTOCO (diazepam) by Neurelis is mechanism of action although the precise mechanism by which diazepam exerts its antiseizure effects is unknown, animal and in vitro studies suggest that diazepam acts to suppress seizures through an interaction with γ-aminobutyric acid (gaba) receptors of the a-type (gaba a ). First approved in 2020.
Drug data last refreshed 6h ago · AI intelligence enriched 1w ago
VALTOCO is a nasal spray formulation of diazepam, a benzodiazepine indicated for acute seizure management. It works by enhancing GABA-mediated inhibition at GABA-A receptors, suppressing excessive neuronal depolarization that drives seizure generation and spread. The nasal route provides rapid onset suitable for emergency seizure intervention.
Product is at peak commercial maturity with 15K+ annual claims, indicating established market presence with stable team requirements.
Mechanism of Action Although the precise mechanism by which diazepam exerts its antiseizure effects is unknown, animal and in vitro studies suggest that diazepam acts to suppress seizures through an interaction with γ-aminobutyric acid (GABA) receptors of the A-type (GABA A ). GABA, the major…
Benzodiazepine
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
A Study to Assess the Time to Onset of Action of Staccato Alprazolam Versus Midazolam and Diazepam in Healthy Participants
Pharmacokinetics Study of VALTOCO® in Pediatric Subjects With Epilepsy
Safety and Tolerability Study of Diazepam Buccal Film (DBF) in Subjects With Epilepsy
Treatment Of Alcohol Withdrawal Syndrome: Dexmedetomidine Vs Diazepam In A Hospital O'horán
Pharmacokinetics and Safety Study of Diazepam Buccal Film (DBF) in Pediatric Subjects With Epilepsy
Worked on VALTOCO at Neurelis? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Upgrade to Pro to access patent cliff timelines and LOE dates and other premium pharma intelligence.
Upgrade to Pro — $25/moUpgrade to Pro to access Medicare Part D spending data and other premium pharma intelligence.
Upgrade to Pro — $25/moUpgrade to Pro to access CMS Part B ASP pricing data and other premium pharma intelligence.
Upgrade to Pro — $25/moVALTOCO roles concentrate in commercial and medical affairs functions, with a small but specialized job pipeline of 4 linked positions across leadership and field levels. Working on this product positions you in a niche, established therapeutic area with limited expansion but strong market entrenchment.
4 open roles linked to this drug